ProQR Therapeutics NV
PRQR · NASDAQ
$1.38+$0.07 (+5.34%)TodayMarket closed ·
Prev close $1.31
Who owns PRQR
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 58.3% of PRQR’s shares.
- Eli Lilly and Company16.5%
- Van Herk Investments11.6%
- Adage Capital Management, L.P.6.8%
- abrdn Inc.6.7%
- Next 6 largest institutions16.7%
- All other shareholders41.7%
| Holder | Shares | % of shares |
|---|---|---|
| Eli Lilly and Company | 22.00M | 16.54% |
| Van Herk Investments | 15.38M | 11.57% |
| Adage Capital Management, L.P. | 9.02M | 6.78% |
| abrdn Inc. | 8.93M | 6.72% |
| Affinity Asset Advisors LLC | 5.54M | 4.17% |
| Privium Fund Management BV | 5.47M | 4.11% |
| Ikarian Capital LLC | 3.43M | 2.58% |
| Woodline Partners LP | 3.28M | 2.46% |
| Heights Capital Management, Inc. | 2.76M | 2.08% |
| Sphera Funds Management Ltd. | 1.76M | 1.32% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| abrdn World Healthcare Fund | 3.32M | 2.49% |
| Platinum International Health Sciences Fund | 1.24M | 0.93% |
| Nomura Healthcare Fund | 620.00K | 0.47% |
| Fidelity NASDAQ Composite Index Fund | 71.48K | 0.05% |
| Xtrackers S&P 500 Swap UCITS ETF | 56.84K | 0.04% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $1.11M (4 trades) of PRQR on the open market, with no sales.
| Insider | Type | Shares | Value |
|---|---|---|---|
| de Boer Daniel Anton | Buy | 200.00K | $353.96K |
| Filius Bart | Buy | 150.00K | $257.92K |
| de Boer Daniel Anton | Buy | 150.00K | $261.00K |
| de Boer Daniel Anton | Buy | 150.00K | $238.50K |
| Hinsch Gylvin Lykke | Award | 14.49K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 2.87M
- Days to cover
- 4.95
- % of shares outstanding
- 2.16%
- Average daily volume
- 579.12K
- Change since last report
- +19.2%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.